San Francisco, United States
Atomwise, founded in 2012, is a pioneering preclinical pharma company based in the United States. Operating at the intersection of AI, Biotechnology, and Health Care, it aims to deliver on its slogan: Better Medicines Faster.
The company has set a milestone by expanding its Board of Directors and creating a Scientific Advisory Board, bolstering its internal drug discovery pipeline. Leveraging its proprietary AtomNet® technology, Atomwise leads the AI-driven structure-based drug discovery domain. It is addressing over 600 unique disease targets through partnerships with more than 250 global entities, including major pharmaceutical and biotechnology firms.
With over $174 million raised from top venture capital firms, and a recent $2.30M grant from the Bill & Melinda Gates Foundation in October 2020, Atomwise is well-positioned to innovate at a time when new medicines are crucial. The company's mission aligns with leveraging cutting-edge technology to solve complex problems and potentially save one billion lives.
